Vanda Pharmaceuticals
VNDA
Vanda Pharmaceuticals (VNDA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.04
- EPS estimate
- −$0.58
- EPS surprise
- −78.54%
- Revenue surprise
- −18.40%
- Revenue
- $50.5M
- Revenue estimate
- $61.9M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.58 | −$1.04 | −78.54% | $50.5M | SEC |
| Q1 2026 | May 6, 2026 | −$0.69 | −$0.82 | −19.19% | $51.7M | SEC |
| Q4 2025 | Feb 11, 2026 | −$0.98 | −$2.39 | −145.13% | $57.2M | SEC |
| Q3 2025 | Oct 29, 2025 | −$0.43 | −$0.38 | +12.30% | $56.3M | SEC |
| Q2 2025 | Jul 31, 2025 | −$0.36 | −$0.46 | −28.96% | $52.6M | SEC |
| Q1 2025 | May 7, 2025 | −$0.57 | −$0.50 | +12.79% | $50.0M | SEC |
| Q4 2024 | Feb 13, 2025 | −$0.11 | −$0.08 | +25.02% | $53.2M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.16 | −$0.09 | +42.57% | $47.7M | SEC |
| Q2 2024 | Jul 31, 2024 | −$0.19 | −$0.08 | +57.89% | $50.5M | SEC |
| Q1 2024 | May 8, 2024 | $0.05 | −$0.07 | −240.00% | $47.5M | SEC |
| Q4 2023 | Feb 7, 2024 | −$0.09 | −$0.04 | +55.56% | $45.3M | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.04 | $0.00 | +100.00% | $38.8M | SEC |
| Q2 2023 | Jul 27, 2023 | −$0.13 | $0.03 | +123.08% | $46.1M | SEC |
| Q1 2023 | May 3, 2023 | $0.00 | $0.06 | +0.00% | $62.5M | SEC |
| Q4 2022 | Feb 8, 2023 | $0.08 | $0.12 | +50.00% | $64.5M | SEC |
| Q3 2022 | Nov 2, 2022 | $0.10 | $0.06 | −40.00% | $65.3M | SEC |
| Q2 2022 | Aug 3, 2022 | $0.14 | $0.05 | −64.29% | $64.4M | SEC |
| Q1 2022 | May 5, 2022 | −$0.01 | −$0.11 | −1000.00% | $60.2M | SEC |
| Q4 2021 | Feb 23, 2022 | $0.09 | $0.12 | +41.18% | $68.0M | SEC |
| Q3 2021 | Nov 3, 2021 | $0.19 | $0.14 | −26.32% | $70.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Vanda Pharmaceuticals (VNDA) last report earnings?
Vanda Pharmaceuticals last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did VNDA beat earnings estimates?
No. Vanda Pharmaceuticals reported EPS of −$1.04 for Q2 2026 against a −$0.58 estimate — a 78.54% miss.
How much revenue did VNDA report last quarter?
Vanda Pharmaceuticals reported $50.5M in revenue for Q2 2026, against a consensus estimate of $61.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.